Identification | Back Directory | [Name]
Ublituximab | [CAS]
1174014-05-1 | [Synonyms]
Ublituximab Ublituximab (DHC90706) Research Grade Ublituximab(DHC90706) |
Hazard Information | Back Directory | [Uses]
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects[1]. | [References]
[1] Matthew Lunning, et al. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019 Nov 21;134(21):1811-1820. DOI:10.1182/blood.2019002118 |
|
Company Name: |
Biolab Reagents
|
Tel: |
18108604356 18108604356 |
Website: |
www.biolabreagent.com/ |
Company Name: |
Cell Sciences
|
Tel: |
9785721070 |
Website: |
www.cellsciences.com |
|